AstraZeneca and Amgen have announced positive topline results from the Phase III WAYPOINT trial of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The study met its co-primary endpoints, demonstrating a statistically significant and clinically meaningful reduction in nasal polyp size and nasal congestion compared to placebo.
The WAYPOINT study (NCT04851964) enrolled 416 patients with severe CRSwNP. The co-primary endpoints were the change from baseline at 52 weeks in total nasal polyp size, measured by the endoscopic total Nasal Polyp Score, and the change from baseline in bi-weekly mean nasal congestion, measured by the participant-reported Nasal Congestion Score. Detailed results will be shared with regulatory authorities and the scientific community at an upcoming medical meeting.
Mechanism of Action and Prior Approvals
Tezspire is a thymic stromal lymphopoietin (TSLP) inhibiting monoclonal antibody. TSLP is a key cytokine in the immune system that promotes inflammation. Tezspire was approved by the US FDA as a treatment for severe asthma in 2021. The drug generated $86 million in sales in 2023.
Competitive Landscape
The primary competitor to Tezspire in this space is Sanofi and Regeneron’s Dupixent (dupilumab), which is already approved for CRSwNP and other immune-mediated disorders. Dupixent generated €10.7 billion ($11.6 billion) in global sales last year. GlobalData forecasts Tezspire to generate $3.6 billion in sales by 2030.
Further Development
Amgen and AstraZeneca are also investigating Tezspire in other conditions such as chronic spontaneous urticaria and eosinophilic esophagitis (EoE). In 2021, Tezspire received an Orphan Drug Designation from the US FDA for the treatment of EoE.
